Established as a partnership in global health, the Global Fund works closely with a wide diversity of partners –implementing governments, donors, civil society, international development organizations, the private sector and communities living with and affected by the diseases. This partnership model actively supports country-owned approaches that develop and implement effective, evidence-based programs to respond to AIDS, tuberculosis and malaria.
18 July 2012
Geneva –The Global Fund to Fight AIDS, Tuberculosis and Malaria today made public a preliminary report of an independent evaluation of the pilot phase of the Affordable Medicines Facility–malaria, also known as AMFm.
The Global Fund commissioned the independent evaluation to assess the extent to which AMFm has achieved the main objectives laid out for its pilot phase, which ends in December 2012. The independent evaluation was mandated by the Global Fund Board and will inform its decision in November 2012, when the Board is expected to consider the future of AMFm beyond the pilot phase.
The preliminary report is now available here. The final report will be available in late August.
The goal of AMFm is to improve access to artemisinin-based combination therapies (ACTs), the most effective anti-malaria treatment, saving lives and delaying the onset of widespread resistance to this class of medicines. The AMFm pilot phase was launched in April 2009 and began operations in July 2010. It set out to increase availability, particularly through private outlets where most people seek their treatments, and drive down the price of ACTs through a factory-gate global subsidy of ACTs combined with country-level measures to support its implementation.
The AMFm pilot phase currently operates in seven countries: Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania, and Uganda. The independent evaluation assessed the program in each of the pilot countries.
To date, AMFm has subsidized nearly 270 million ACT treatments. This global subsidy is financed through contributions of US$336 million from UNITAID, the governments of the United Kingdom and Canada, and the Bill & Melinda Gates Foundation. Technical support is provided by members of the Roll Back Malaria Partnership.
The independent evaluation of the AMFm pilot phase was led by a consortium of ICF International and the London School of Hygiene and Tropical Medicine, which were contracted through a competitive tender process. In addition, the Global Fund contracted Data Contributors that were responsible for the fieldwork, data analysis, and country reports.
Contact | Report Fraud and Abuse | Legal | RSS | Sitemap
© 2014 The Global Fund to Fight AIDS, Tuberculosis and Malaria